A phase I/II study in relapsed/refractory FLT3-mutated AML showed a 57.5% overall response rate and 47.2% composite CR rate—CR, CRi, and CR with incomplete platelet recovery (CRp)—in 106 patients receiving doses of 80 mg daily or higher85. The gene discussed is FLT3; the disease is acute myeloid leukemia.